ActivePhase 4ACTRN12609000593235

Efficacy of Zoledronate in fracture prevention in osteopenic postmenopausal women.

Sponsor

Professor Ian Reid

Enrollment

2,000 participants

Start Date

Sep 28, 2009

Study Type

Interventional

Conditions

Fractures in women with Postmenopausal osteopenia

Summary

This study is to determine whether the administration of the bone strengthening drug Zoledronate will reduce the numbers of fractures occurring in women who have low bone density but whose densities are not low enough to be classified as having osteoporosis.

Eligibility

Sex: FemalesMin Age: 65 YearssMax Age: 85 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests whether a yearly infusion of zoledronate (a bone-strengthening medication) can prevent fractures in postmenopausal women aged 65-85 who have mildly reduced bone density (osteopenia) but not yet osteoporosis.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Intravenous Zoledronate 5mg/100ml infused over 15 minutes every 18 months for 6 years (4 injections at Baseline, 18,36and 54 months)

Locations(1)

New Zealand

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12609000593235